From Wikipedia, the free encyclopedia
Jump to: navigation, search

Medarex ( former NASDAQ symbol: MEDX ) is an American biotechnology company owned by Bristol Myers Squibb and based in Princeton, New Jersey.

Medarex is developing monoclonal antibodies to CTLA-4 and PD-1, which are proteins on the surface of T cells. T cells attack cancer cells, but CTLA-4 and PD-1 act as brakes on the T cell's anti-cancer activities. The monoclonal antibodies bind to those proteins, and release the T cell to attack cancer cells.[1][2]

In 2009, the U.S. FDA approved Simponi, a human monoclonal antibody for treatment for arthritis, which was co-developed with Johnson & Johnson's Janssen Biotech.[3] In 2011, the U.S. Food and Drug Administration approved Ipilimumab, a monoclonal antibody to CTLA-4, for treatment of metastatic melanoma. The cost is $120,000 for a cost of treatment.[1]

The company has manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California.


Medarex was founded by Donald Drakeman. The company went public in 1991, with 2,300,000 shares of common stock at $6.10 per share and 2,250,000 Redeemable Warrants offered at its IPO.[4] The company's second president and CEO was Howard H. Pien, succeeding Drakeman in 2007.[5] Genmab was founded as a European spin-off of American Biotech company Medarex in February 1999.

The company was acquired by Bristol Myers Squibb in 2009.[6]


  1. ^ a b Breakthrough of the Year: Cancer Immunotherapy, Science 20 December 2013, Vol. 342 no. 6165 pp. 1432-1433, DOI: 10.1126/science.342.6165.1432, Jennifer Couzin-Frankel
  2. ^ NCT00094653
  3. ^ Marcial, Gene (4 May 2009). "Marcial: Medarex, a Bright Spot in Biotech". Retrieved 24 Sep 2014. 
  4. ^ "Medarex raises $12.9M in IPO for R&D of Biospecific". 1 May 1991. Retrieved 24 Sep 2014. 
  5. ^ "Life in the Fast Lane: New at Medarex". 23 May 2007. Retrieved 24 Sep 2014. 
  6. ^ "Bristol-Myers Squibb to Acquire Medarex". 22 Jul 2009. Retrieved 24 Sep 2014. 

External links[edit]